Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21992574 | 0.89 | MEN1 (0.41) | GRM4MEN1GAAMAPTKMT2A | |
| SCHEMBL23605941 | 0.86 | POLB (0.44) | TDP1L3MBTL1GRM4MEN1GAA | |
| SCHEMBL21991269 | 0.85 | TAS2R14 (0.38) | — | |
| SCHEMBL21991268 | 0.84 | APP (0.44) | MEN1GAAMAPTKMT2ANPC1 | |
| SCHEMBL21991937 | 0.82 | TDP1 (0.39) | TDP1L3MBTL1GRM4FFAR1 | |
| SCHEMBL21992559 | 0.81 | HPGD (0.50) | TDP1L3MBTL1KMT2ANPC1CYP1A2 | |
| SCHEMBL21992716 | 0.80 | MTNR1B (0.36) | — | |
| SCHEMBL21991808 | 0.79 | ALDH1A1 (0.47) | TDP1L3MBTL1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL24305884 | 0.78 | CA12 (0.42) | CHRM5GRM4MEN1GAAMAPT | |
| SCHEMBL21991241 | 0.78 | GRM4 (0.39) | TDP1L3MBTL1GRM4MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | TDP1 1445/4885L3MBTL1 1170/4885CHRM5 2922/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | TDP1 1445/4885L3MBTL1 1170/4885CHRM5 2922/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | TDP1 1445/4885L3MBTL1 1170/4885CHRM5 2922/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | TDP1 1445/4885L3MBTL1 1170/4885CHRM5 2922/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | TDP1 1445/4885L3MBTL1 1170/4885CHRM5 2922/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | TDP1 1445/4885L3MBTL1 1170/4885CHRM5 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.